SPA.AU Spacetalk Ltd
Market Closed 05-17 16:12:00 AEST
0.02
+0.00
0.00%
High
0.02
Low
0.02
Vol
172.55K
Open
0.02
D1 Closing
0.02
Amplitude
0.00%
Mkt Cap
8.95M
Tradable Cap
6.28M
Total Shares
471.02M
T/O
3.28K
T/O Rate
0.05%
Tradable Shares
330.67M
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Dow Jones · 05-15
Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
ASX lithium stock suspended for 8 months gearing up to resume trading
MotleyFool · 05-08
ASX lithium stock suspended for 8 months gearing up to resume trading
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
seekingalpha · 04-23
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Press Release: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Dow Jones · 04-17
Press Release: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
seekingalpha · 04-09
BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
seekingalpha · 03-24
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
BUZZ-Australia's Metro Mining hits over 21-mnth high on FY24 forecast
Reuters · 02-29
BUZZ-Australia's Metro Mining hits over 21-mnth high on FY24 forecast
Load more
Introduction
Company Name.
Spacetalk Ltd
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Issue price:
--
{"stockData":{"symbol":"SPA.AU","market":"AU","secType":"STK","nameCN":"Spacetalk Ltd","latestPrice":0.019,"timestamp":1715926320000,"preClose":0.019,"halted":0,"volume":172552,"delay":0,"nameEN":"Spacetalk Ltd","floatShares":330674221,"shares":471021409,"eps":-0.026573,"marketStatus":"Market Closed","change":0,"latestTime":"05-17 16:12:00 AEST","open":0.019,"high":0.019,"low":0.019,"amount":3278,"amplitude":0,"askPrice":0.02,"askSize":591812,"bidPrice":0.019,"bidSize":111803,"shortable":3,"etf":0,"ttmEps":-0.026573,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716163200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.019,"openAndCloseTimeList":[[1715904000000,1715925600000]],"volumeRatio":0.6648116624329902,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/SPA.AU/","defaultTab":"news","newsList":[{"id":"2435524523","title":"Press Release: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435524523","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435524523?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:30","pubTimestamp":1715718600,"startTime":"0","endTime":"0","summary":"Company received written agreement from the U.S. FDA under a Special Protocol Assessment on the design for a Phase 3b trial of NurOwn. Conference call planned for later this quarter to provide update on NurOwn program. NEW YORK, May 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update.-- In April 2024, BrainStorm received written agreement from the U.S. Food. and Drug Administration , under a Special Protocol Assessment ,sclerosis . The SPA agreement validates the clinical trial protocol. and statistical analysis of the planned Phase 3b trial of NurOwn,demonstrating their adequacy for addressing objectives that support a. initiating the Phase 3b study in 2024, after reviewing the protocol with. investigators, securing study site Institutional Review Board approvals,in Muscle and Nerve i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433750740","title":"ASX lithium stock suspended for 8 months gearing up to resume trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2433750740","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2433750740?lang=en_us&edition=fundamental","pubTime":"2024-05-08 08:37","pubTimestamp":1715128677,"startTime":"0","endTime":"0","summary":"It has been a long time since Leo Lithium Ltd shares have been seen on the ASX boards.The Africa-based ASX lithium stock has been out of action since the middle of September.This has been caused by issues arising from the introduction of a new Mining Code in Mali which impacted its Goulamina Lithium Project.This includes Leo Lithium entering into a further binding share sale and purchase agreement to sell its remaining 40% interest in the Goulamina Lithium Project to Ganfeng Lithium for US$342.7 million.The ASX lithium stock advised that the US$342.7 million cash consideration that is payable by Ganfeng Lithium is structured as follows:. US$10.5 million non-refundable deposit to be paid within 10 days of executing the sale and purchase agreement.US$161.0 million payable on completion of the transaction following satisfaction of conditions precedent.US$171.2 million payable on 30 June 2025 or an earlier date.Management notes that US$342.7 million is equivalent to A$0.43 per Leo Lithiu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/08/asx-lithium-stock-suspended-for-8-months-gearing-up-to-resume-trading/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429111214","title":"Spero Therapeutics Delivers On Game Plan To Create Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2429111214","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2429111214?lang=en_us&edition=fundamental","pubTime":"2024-04-23 23:37","pubTimestamp":1713886637,"startTime":"0","endTime":"0","summary":"Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential.Spero has excellen","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413265641/image_1413265641.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413265641/image_1413265641.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685311-spero-therapeutics-delivers-on-game-plan-to-create-shareholder-value","is_publish_highlight":false,"gpt_icon":0},{"id":"2428381339","title":"Press Release: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn","url":"https://stock-news.laohu8.com/highlight/detail?id=2428381339","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2428381339?lang=en_us&edition=fundamental","pubTime":"2024-04-17 06:31","pubTimestamp":1713306660,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn. Dr. Dagher has served as our Chief Development Officer since July 2023. In his new role as Executive Vice President and Chief Medical Officer, Dr. Dagher's responsibilities will include overseeing the planned Phase 3b registration trial of NurOwn. The Company recently announced that it has reached agreement with the U.S. Food & Drug Administration for a Special Protocol Assessment for this trial.Dr. Dagher has over 20 years' of experience in clinical research and development, with a proven track record of leading successful clinical trials and fostering innovation in drug development. Prior to joining Brainstorm he was Chief Medical Officer at Enveric Biosciences where he was responsible for defining the portfolio strategy and advancement of development plans toward regulatory approvals. He began his career in biopharmaceuticals as a medical scientist at GSK, and has se","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2426864167","title":"BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2426864167","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426864167?lang=en_us&edition=fundamental","pubTime":"2024-04-09 18:58","pubTimestamp":1712660304,"startTime":"0","endTime":"0","summary":"BrainStorm Cell Therapeutics traded higher in the premarket Tuesday after announcing that the U.S. FDA has endorsed the design of a late-stage trial for its cell therapy candidate NurOwn for amyotrophic lateral sclerosis, a neurological disease. The company said the regulator sent a written confirmation of a so-called Special Protocol Assessment , validating the critical trial components such as protocol and statistical analysis of its planned Phase 3b study. The two-part trial is expected to start in 2024 across multiple study sites for patients with ALS who are in the earlier stages of the disease. \"We believe that having this SPA in place will help de-risk certain regulatory aspects of the NurOwn clinical program,\" BrainStorm CEO Chaim Lebovits remarked. More on BrainStorm Cell Therapeutics BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financ","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088132-brainstorm-stock-gains-fda-oks-als-trial","is_publish_highlight":false,"gpt_icon":0},{"id":"2421310935","title":"Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie","url":"https://stock-news.laohu8.com/highlight/detail?id=2421310935","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421310935?lang=en_us&edition=fundamental","pubTime":"2024-03-24 12:46","pubTimestamp":1711255584,"startTime":"0","endTime":"0","summary":"Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease.Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiere","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397661322/image_1397661322.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397661322/image_1397661322.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4680108-aldeyra-derisked-biotech-eyeing-path-to-approval-and-finalizing-deal-with-abbvie","is_publish_highlight":false,"gpt_icon":0},{"id":"2415551918","title":"BUZZ-Australia's Metro Mining hits over 21-mnth high on FY24 forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2415551918","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2415551918?lang=en_us&edition=fundamental","pubTime":"2024-02-29 11:06","pubTimestamp":1709176017,"startTime":"0","endTime":"0","summary":"** Shares of Metro Mining rise 6.9% to A$0.030, their highest since May 2022; last up 3.5% ** Bauxite miner sets forecast for production and shipment at 6.3 mln to 6.8 mln wet metric tonnes for 2024 ** Says underlying EBITDA improved to A$18.5 mln compared to loss of A$24.8 mln ** About 12 mln shares change hands, compared with the 30-day average volume of 6.6 mln shares ** Stock up 42.9% so far this year ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mgmwireless.com","stockEarnings":[{"period":"1week","weight":-0.1364},{"period":"1month","weight":-0.24},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":-0.4412},{"period":"ytd","weight":-0.2692}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0587},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.070157},{"month":2,"riseRate":0.25,"avgChangeRate":0.028846},{"month":3,"riseRate":0.5,"avgChangeRate":-0.026618},{"month":4,"riseRate":0,"avgChangeRate":-0.207507},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.035986},{"month":6,"riseRate":0.666667,"avgChangeRate":0.065392},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035088},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.054579},{"month":9,"riseRate":0,"avgChangeRate":-0.102484},{"month":10,"riseRate":0,"avgChangeRate":-0.166005},{"month":11,"riseRate":0.25,"avgChangeRate":0.013321},{"month":12,"riseRate":0.5,"avgChangeRate":0.063882}],"exchange":"ASX","name":"Spacetalk Ltd","nameEN":"Spacetalk Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spacetalk Ltd(SPA.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spacetalk Ltd(SPA.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spacetalk Ltd,SPA.AU,Spacetalk Ltd股票,Spacetalk Ltd股票老虎,Spacetalk Ltd股票老虎国际,Spacetalk Ltd行情,Spacetalk Ltd股票行情,Spacetalk Ltd股价,Spacetalk Ltd股市,Spacetalk Ltd股票价格,Spacetalk Ltd股票交易,Spacetalk Ltd股票购买,Spacetalk Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spacetalk Ltd(SPA.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spacetalk Ltd(SPA.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}